MALMO, Sweden, March 17, 2017 /PRNewswire/ --
Acarix AB (publ) ("Acarix") today announced the resultsfrom a new multi-center trial of its handheld CADScorŽSystem for non-invasive, non-radiation acoustic detection of Coronary Artery Disease ("CAD"). The results are
(Photo: http://mma.prnewswire.com/media/478910/Acarix.jpg )
The CADScorŽSystem combines acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a handheld device to provide a patient specific CAD-score in less than 10 minutes. The research was led by Principal Investigator Morten Böttcher, MD PhD FESC and by Simon Winther, MD PhD, Department of Cardiology, Aarhus University Hospital, Denmark: "Despite the availability of improved risk stratification algorithms, the incidence of normal investigations such as nuclear or CT imaging remains high. We therefore tested the diagnostic accuracy of the CADScorŽSystem for ruling out CAD to see if it could be used to reduce demand for more advanced diagnostic modalities. We have concluded that, with its ability to rule out CAD with a 97% negative predictive value, this advanced, easy to use, stethoscope like device could indeed be deployed as a frontline test ."
A CAD-score was recorded in all 1,675 patients enrolled in the trial. Low risk was indicated by a CAD-score value ?20. Diagnostic performance evaluated by receiver operating characteristic curve showed an accuracy of: 72% (CI: 67% - 77%). CAD-score cut-off ?20 had an accuracy of:
Sensitivity: 81% (CI: 74% to 88%)
Specificity: 53% (CI: 50% to 56%)
PPV: 15% (CI: 13% to 18%)
NPV: 97% (CI:95% to 98%)
Acarix CEO Søren Rysholt Christiansen commented: "Coronary Artery Disease affects more than 120 million people worldwide but the current diagnostic pathway, which can rapidly escalate to expensive imaging and coronary angiography, is inefficient. A recent Danish study showed that more than 90% of patients presenting with chest pain symptoms to their general practitioner do not have CAD. If adopted, the CADScorŽSystem can provide rapid frontline assessment which could translate into a potential reduction in patient referrals by ~50%. - a win-win for patients, payers and physicians."
For a comprehensive press release, see http://www.acarix.com.
Contacts: Acarix A/S Søren Rysholt Christiansen, CEO E-mail: firstname.lastname@example.org Phone: +45-2777-1112
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All